Log in to post a reply
Jan 13, 2019 08:03AM
Just within the past couple of weeks, two new clinical trials were announced that combine the immunotherapy, Keytruda, with an EP4 inhibitor, which is the same type of drug combo that Kattysmith is taking (Opodivo plus EP4 inhibitor). Clearly big pharma is moving fast to try out this combination, it will be so interesting to see if this works, and if so, how fast the system can move a drug along if its promising! The FDA will expedite consideration of any positive results coming from trials that include immunotherapy.
So, will ER-positive MBCs respond to this combo?! Exciting!!!
Here are links, its not clear if the trials are opened yet or just announced:
One trial for Keytruda will be open to all cancers https://www.prnewswire.com/news-releases/adlai-nor...
and the notice adds: "Based on preliminary results, it is well tolerated in patients with solid tumors. This collaboration is supported by our recent preclinical data demonstrating the potential ability of AN0025 (EP4 Antagonist) to rescue patients who do not initially respond to anti-PD-1 therapy alone or who are resistant to PD-1 inhibitors with solid tumors."
Hedging their bets, the other trial will combine Keytruda with a different EP4 inhibitor, but this trial is restricted to colon and lung cancers:
Prostaglandin E2 (PGE2) has been shown to contribute to an immunosuppressive environment in cancer by enhancing the activity of regulatory immune cells and suppressing the activity of effector immune cells. EP4 is a high-affinity receptor of PGE2 and is known to facilitate these immunosuppressive activities. ARY-007 is an oral, potent and highly selective antagonist of EP4. In preclinical models, EP4 inhibition leads to antitumor activity and also significantly enhances the antitumor activity of checkpoint inhibitors. While in development for a non-oncology indication, ARY-007 was found to be well-tolerated in multiple studies which enrolled approximately 1000 human subjects..
The firm is highly optimistic that the proposed combination of KEYTRUDA & AN0025 (EP4 Antagonist) would be able to offer relevant clinical advantage to patients living with solid tumors.
10/2003, IDC, Stage IIB, ER+/PR+, HER2-
7/2015, Stage IV, metastasized to bone, ER+/PR-, HER2-